

Press release  
May 29, 2009  
Gothenburg

## Change in the number of shares in Vitrolife AB (publ)

The total number of shares in Vitrolife AB (publ) at May 29, 2009 amounts to 19,552,857, corresponding to 19,552,857 votes. The change in the number of shares and votes is due to the resolution at the Annual General Meeting on April 27, 2009 to reduce the number of shares through the cancellation of 247,300 of the company's own shares bought back by the company.

May 29, 2009  
Gothenburg

Magnus Nilsson  
CEO

**Queries should be addressed to:**

Magnus Nilsson, CEO, phone +46 31 721 80 61  
Eva Nilsagård, CFO, phone +46 31 721 80 13

---

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and its products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and the USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Friday May 29, 2009 at 8.30 am.